Table 1.

Review of the literature regarding primary breast rhabdomyosarcoma in the pediatric population

Author [ref.]	Year	Pathologic subtype	Age, years	Cases, n	Location	Lymph node status	Size, mm	Neoadjuvant therapy	Surgery	Adjuvant therapy	Follow-up duration	Status
Torres and Ferrer [21]	1985		11	1	bilateral
Altomare et al. [20]	1989		15	1				ChT				died
Reale et al. [17]	1994	embryonal	16	1
Rogers et al. [18]	1994	alveolar	14	1	right				wide excision	multiagent ChT
Boothroyd and Carty [19]	1994		12	1	left			ChT + RT
Hays et al. [16]	1997	alveolar (5) embryonal (1) NOS (1)	11–20	7							3.9–7 years
Herrera and Lugo-Vicente [9]	1998	embryonal	13	1	right	negative	6×4		simple mastectomy	VAC	12 months	remission
Binokay et al. [8]	2003	alveolar	16	1	right	positive	6×10		MRM
Vishnevskaia et al. [14]	2003	alveolar	14	3	bilateral						3–18 months	died
Pandey et al. [15]	2004	embryonal	12	1			15		quadrantectomy	VAC + RT	73 months	remission
Vranic et al. [38]	2006		10	1
Nogi et al. [11]	2007	alveolar	13	1	left	positive	13×8		MRM	doxorubicin, ifosfamide, actinomycin D	6 months	remission
Kallianpur et al. [13]	2015		19	1	right	negative	30×20		simple mastectomy	ifosfamide + adriamycin + RT	2 months	remission
Pareekutty et al. [12]	2016	alveolar	12	1	right	positive	90×90	ChT	MRM	IRS-IV protocol + RT	35 months	remission
Sugar and Sapi [22]	1988	alveolar	14	1
Da Silva et al. [10]	2007	embryonal	15	1	right	positive
Present case	2017	alveolar	12	1	left	positive	40×45	ChT	simple mastectomy	VAC+ RT	34 months	remission

NOS = Not specified; ChT = chemotherapy; MRM = modified radical mastectomy; RT = radiotherapy; IRS-IV = Intergroup Rhabdomyosarcoma Study-IV; VAC = vincristine, actinomycin D, cyclophosphamide.